(Q43761790)

English

Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

6

object named as

Lorne A Babiuk

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

5

object named as

George Mutwiri

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Doo-Hee Shim

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Hyun-Jeong Ko

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Gerdts Volker

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Andrew A Potter

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Mi-Na Kweon

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

0 references

publication date

8 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

2311-2317

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Let's go mucosal: communication on slippery ground

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

New generation of mucosal adjuvants for the induction of protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

The mechanism of cholera toxin adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Poly(I:C)-Treated human langerhans cells promote the differentiation of CD4+ T cells producing IFN-gamma and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Polymeric carriers for oral uptake of microparticulates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene].

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Sublingual vaccination with influenza virus protects mice against lethal viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

The immune geography of IgA induction and function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Protein release from polyphosphazene matrices

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.069

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.12.069

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43761790&oldid=2103114808"